NeoImmuneTech (XKRX:950220) Debt-to-Asset : 0.04 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NeoImmuneTech Debt-to-Asset?

NeoImmuneTech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩1,352.62 Mil. NeoImmuneTech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩2,555.30 Mil. NeoImmuneTech's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was ₩90,511.43 Mil. NeoImmuneTech's debt to asset for the quarter that ended in Dec. 2023 was 0.04.

NeoImmuneTech Debt-to-Asset Historical Data

The historical data trend for NeoImmuneTech's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoImmuneTech Debt-to-Asset Chart

NeoImmuneTech Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

0.02

0.03

0.04

NeoImmuneTech Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial											0.04	0.04	0.04	0.04	0.04

Competitive Comparison of NeoImmuneTech's Debt-to-Asset

For the Biotechnology subindustry, NeoImmuneTech's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeoImmuneTech's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeoImmuneTech's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where NeoImmuneTech's Debt-to-Asset falls into.

NeoImmuneTech Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

NeoImmuneTech's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1352.622	+	2555.296)	/	90511.432
	=	0.04

NeoImmuneTech's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1352.622	+	2555.296)	/	90511.432
	=	0.04

NeoImmuneTech (XKRX:950220) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

NeoImmuneTech Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of NeoImmuneTech's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

NeoImmuneTech (XKRX:950220) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeoImmuneTech Inc (XKRX:950220) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

2400 Research Boulevard, Suite 250, Rockville, MD, USA, 20850

Website

http://www.neoimmunetech.com

NeoImmuneTech Inc is a clinical-stage T cell-focused biotech company dedicated to the discovery and development of novel immuno-therapeutics. Its lead asset NT-I7 is the clinical stage IL-7, which enhances the body's immune function to address key resistance mechanisms in Immuno-Oncology and deadly infectious diseases.

NeoImmuneTech (XKRX:950220) Headlines

No Headlines